“We note that the company has enrolled another roughly 118 patients with the goal of seeking accelerated approval. As noted in Tuesday’s press release, management expects to provide a regulatory update by the end of the year .”,” the firm’s analyst commented.
GBT has been the topic of several other research reports. Cantor Fitzgerald set a $96.00 price objective on Global Blood Therapeutics and gave the stock a buy rating in a report on Tuesday, October 2nd. Zacks Investment Research cut Global Blood Therapeutics from a buy rating to a hold rating in a report on Friday, July 20th. BidaskClub cut Global Blood Therapeutics from a hold rating to a sell rating in a report on Wednesday, September 19th. HC Wainwright set a $125.00 price objective on Global Blood Therapeutics and gave the stock a buy rating in a report on Thursday, September 13th. Finally, ValuEngine cut Global Blood Therapeutics from a strong-buy rating to a buy rating in a report on Tuesday, October 2nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of $80.20.
Global Blood Therapeutics (NASDAQ:GBT) last posted its quarterly earnings data on Tuesday, November 6th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.02. During the same period last year, the firm posted ($0.66) EPS. Equities research analysts anticipate that Global Blood Therapeutics will post -3.39 earnings per share for the current year.
In related news, insider Lesley Ann Calhoun sold 2,004 shares of Global Blood Therapeutics stock in a transaction on Friday, August 17th. The stock was sold at an average price of $49.89, for a total value of $99,979.56. Following the transaction, the insider now owns 1,342 shares in the company, valued at $66,952.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.40% of the stock is currently owned by company insiders.
A number of large investors have recently added to or reduced their stakes in the business. FMR LLC raised its position in Global Blood Therapeutics by 21.0% in the third quarter. FMR LLC now owns 7,807,836 shares of the company’s stock valued at $296,698,000 after purchasing an additional 1,357,642 shares during the period. BlackRock Inc. increased its position in shares of Global Blood Therapeutics by 1.1% during the third quarter. BlackRock Inc. now owns 4,186,269 shares of the company’s stock worth $159,079,000 after acquiring an additional 43,507 shares during the last quarter. Janus Henderson Group PLC increased its position in shares of Global Blood Therapeutics by 12.2% during the second quarter. Janus Henderson Group PLC now owns 4,154,385 shares of the company’s stock worth $187,778,000 after acquiring an additional 452,843 shares during the last quarter. Northern Trust Corp increased its position in shares of Global Blood Therapeutics by 25.1% during the second quarter. Northern Trust Corp now owns 602,689 shares of the company’s stock worth $27,241,000 after acquiring an additional 121,043 shares during the last quarter. Finally, Nexthera Capital LP increased its position in shares of Global Blood Therapeutics by 28.2% during the second quarter. Nexthera Capital LP now owns 404,092 shares of the company’s stock worth $18,265,000 after acquiring an additional 88,945 shares during the last quarter. 99.01% of the stock is currently owned by institutional investors.
Global Blood Therapeutics Company Profile
Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.
Further Reading: What is a Call Option?
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.